These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 25916406)

  • 1. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ; Li S; Li JJ
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
    Christiansen MK; Jensen HK
    Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.
    Yoon CH; Watson K
    Ann Pharmacother; 2014 Feb; 48(2):238-49. PubMed ID: 24259646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
    Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
    J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies.
    Verma DR; Brinton EA
    Rev Cardiovasc Med; 2014; 15(2):86-101; quiz 101. PubMed ID: 25051126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 inhibitors--past, present and future.
    Reiner Ž
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1517-21. PubMed ID: 26329686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).
    Ferdinand KC; Nasser SA
    Cardiovasc Drugs Ther; 2015 Jun; 29(3):295-308. PubMed ID: 26068408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 antibodies for the treatment of hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Nutrients; 2014 Dec; 6(12):5517-33. PubMed ID: 25470376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9.
    Stein EA; Raal F
    Annu Rev Med; 2014; 65():417-31. PubMed ID: 24422577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody.
    Roth EM; Diller P
    Future Cardiol; 2014 Mar; 10(2):183-99. PubMed ID: 24762246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.